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Abstract Alterations in mitochondrial metabolism
have been described as one of the major hallmarks of
both ageing cells and cancer. Age is the biggest risk
factor for the development of a significant number of
cancer types and this therefore raises the question of
whether there is a link between age-related mitochon-
drial dysfunction and the advantageous changes in
mitochondrial metabolism prevalent in cancer cells. A
common underlying feature of both ageing and cancer
cells is the presence of somatic mutations of the
mitochondrial genome (mtDNA) which we postulate
may drive compensatory alterations in mitochondrial
metabolism that are advantageous for tumour growth.
In this review, we discuss basic mitochondrial func-
tions, mechanisms of mtDNA mutagenesis and their
metabolic consequences, and review the evidence for
and against a role for mtDNA mutations in cancer
development.
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Mitochondrial function
Mitochondria are present in most eukaryotic cells and
are dynamic, intracellular double-membrane bound
organelles, which function in a variety of roles to
maintain cellular homeostasis. It is thought that the
mitochondrion descended from a free-living a-pro-
teobacterium that formed a symbiotic relationship
within a host cell (Gray 2012; Gray et al. 1999).
During mitochondrial evolution, loss or transfer of the
majority of genes from the a-proteobacterium to the
nuclear genome has occurred (Karlberg et al. 2000).
Subsequently, mitochondria are reliant on the import
of nuclear encoded gene products for biogenesis,
maintenance and function. However, a small
(* 16 kb) circular genome remains known as mito-
chondrial DNA (mtDNA), which is essential for one of
the major functions of mitochondria; adenosine
triphosphate (ATP) synthesis through oxidative phos-
phorylation (OXPHOS). Other important mitochon-
drial functions include iron–sulphur biogenesis and
haem synthesis (Sano et al. 1959), fatty acid synthesis
and oxidation (Hiltunen et al. 2009; Houten and
Wanders 2010), one carbon metabolism (Ducker et al.
2016), regulation of reactive oxygen species (ROS),
(Diebold and Chandel 2016), calcium homeostasis
(Gunter et al. 2000), and induction of apoptosis (Liu
et al. 1996). Below we describe in detail some of the
normal mitochondrial functions that have been shown
to be dysregulated in ageing and cancer (Fig. 1).
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Oxidative phosphorylation
An array of metabolic pathways present within a cell
interconnect to convert stored energy from
carbohydrates, proteins and fats into energy the cell
can utilise in the form of ATP. During glycolysis,
glucose molecules enter a series of chemical reactions
resulting in the reduction of two nicotinamide
Fig. 1 Central carbon metabolic pathways important for
cellular energy production and biosynthetic reactions. In the
cytoplasm, glycolysis can directly lead to the anaerobic
generation of lactate and ATP. Alternatively, in the presence
of oxygen acetyl CoA feeds into the mitochondrial TCA cycle to
generate electron donors for ATP synthesis via OXPHOS.
Depending on the metabolic requirements of the cell, glycolytic
intermediates may be diverted into the pentose phosphate and
serine synthesis pathways. The SSP produces one-carbon units
that supply metabolic pathways such as the mitochondrial and
cytoplasmic folate cycles, purine synthesis, transsulfuration and
the methyl cycle. THF tetrahydrofolate
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adenosine dinucleotide (NAD?) molecules to NADH,
the generation of two ATP molecules and two
pyruvate molecules per glucose molecule. Pyruvate
is transported into the mitochondrion where it is
decarboxylated to acetyl-coenzyme A (acetyl coA) to
allow entry into the tricarboxylic acid (TCA) cycle.
One complete turn through the TCA cycle permits the
phosphorylation of guanosine-50triphoshate (GDP),
reduction of three NAD? molecules to three NADH
molecules and the reduction of one flavin adenine
dinucleotide (FAD) to FADH2 (Cooper 2000).
NADH and FADH2 are both electron donors for
energy generation by OXPHOS (Mitchell 1961). In
this process electrons are transferred from NADH and
FADH2, along the mitochondrial electron transport
chain (ETC), which is composed of protein–lipid
enzyme complexes (I–IV) located in the inner mito-
chondrial membrane (IMM), and is coupled via proton
pumping to the phosphorylation of adenosine diphos-
phate (ADP) to ATP by complex V. Electrons entering
the ETC at complex I are transferred to ubiquinone
(Q), a lipid soluble molecule, which is reduced to
ubiquinol (QH2) and carries the electrons through the
mitochondrial membrane to complex III (cytochrome
c oxido-reductase). Catalysis of electrons transferred
from NADH through complex I to Q, is coupled to the
pumping of four protons into the intermembrane space
(Hinkle et al. 1991). Electrons donated to complex III
from QH2, which is re-oxidised to ubiquinone, are
transferred from cytochrome b in complex III to the
haem protein, cytochrome c, in the peripheral mem-
brane (Hatefi 1985). The catalysis of 2e- by complex
III to cytochrome c is coupled to the translocation of
2H? ions into the intermembrane space (Hinkle et al.
1991). Cytochrome c carries electrons to the final
complex of the ETC complex IV (cytochrome c oxi-
dase), which catalyses the irreversible reduction of O2,
to form H2O (Hatefi 1985). Electrons transferred from
FADH2 to the exclusively nuclear encoded complex II
(succinate dehydrogenase), are passed to Q. Complex
II (also a participant in the TCA cycle) oxidises
succinate to fumarate (Huang and Millar 2013);
however, electrons transferred from FADH2 to
ubiquinone do not release a sufficient amount of free
energy for proton pumping. Only free energy yielded
at complexes I, III and IV is coupled to the translo-
cation of protons from the matrix across the IMM into
the intermembrane space (Hinkle et al. 1991). This
sets up an electrochemical gradient across the
mitochondrial membrane providing a proton motive
force that complex V (ATP synthase) utilizes to
phosphorylate ADP to ATP (Hatefi 1985). Movement
of protons through the membrane embedded cylindri-
cal F0 domain of complex V, drives the rotation of a
central c subunit (Noji et al. 1997). This rotational
motion causes a conformational change of b chains in
the ATP synthase F1 domain of complex V and the
synthesis of ATP from ADP and inorganic phosphate
(Noji et al. 1997).
ROS production
Mitochondria are the major source of cellular ROS
production (Loschen et al. 1971), including superox-
ide, hydrogen peroxide and the hydroxyl radical.
Produced by the reduction of O2 with unpaired
electrons, ROS are highly reactive molecules. A
traditional view of ROS centres on their negative role
in oxidative stress where they cause damage to cellular
proteins, DNA and lipids, and are thought to con-
tribute to disease and ageing (Harman 1956, 1972).
Potential sites of endogenous ROS production include
enzymes with Flavin-containing prosthetic groups
including FAD or Flavin mononucleotide; and
enzymes involved in the TCA cycle, ETC and fatty
acid oxidation. Within the mitochondria the ETC
produces ROS at complexes I and III as by-products
during OXPHOS (Sugioka et al. 1988; Turrens and
Boveris 1980). Delays during the transfer of electrons
down the transport chain facilitates the reaction of
stalled electrons with O2, producing the free radial
superoxide. Furthermore, the strong electrical field
produced by the potential difference between the
matrix and inter-membrane space can cause a diver-
gence of electrons in the IMM along their path. This
electrical field can act as a force, accelerating the
movement of superoxide anions formed within the
IMM towards the inter-membrane space and thus are
more readily accessible to the cytosol (reviewed by
Sabharwal and Schumacker 2014).
Prime targets of oxidative damage are therefore
mitochondrial enzymes, lipids and mtDNA, which lie
in close proximity to the ETC. However mitochondria,
do possess their own antioxidant, mitochondrial
superoxide dismutase, to scavenge high levels of
damaging ROS (McCord and Fridovich 1969; Weisi-
ger and Fridovich 1973). More recently, ROS have
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been shown to participate in signal transduction
oxidation–reduction reactions, primarily oxidising
cysteine residues of a range of target proteins to help
control important physiological processes (Janssen-
Heininger et al. 2008). For example ROS help regulate
responses to growth factor stimulation, metabolic
excess, low oxygen availability, stresses such as
double-stranded DNA breaks, as well as provide
signals to regulate autophagy and the inflammatory
response (Finkel 2011). Thus, mitochondria play a
central role in maintaining homeostasis of ROS levels
that are essential for physiological functioning but at
high levels can be toxic to a cell (reviewed by (Diebold
and Chandel 2016).
Apoptosis
Apoptosis, also referred to as programmed cell death,
is a carefully orchestrated and evolutionarily con-
served mechanism for maintaining a healthy cell
population, protection against genotoxic stress and
pathogen invasion, and the growth and development of
an organism (Wang and Youle 2009). Within a cell
there are two different apoptotic pathways which are
activated by different signals; the intrinsic and the
extrinsic pathway. The extrinsic pathway is dependent
on cell surface death receptors, whereas the intrinsic
pathway is dependent on mitochondrial functioning.
Various studies show a crossover and interaction of
these two pathways (Li et al. 1998; Luo et al. 1998),
with functioning of the mitochondrial dependent
apoptotic pathway being essential (Li et al. 2000).
Dysregulation of the latter pathway has been shown to
lead to abnormal development and disease (Jones et al.
2003; Zhang et al. 2003).
Both pathways involve a cascade of molecular
events with cysteine proteases, termed caspases that
controllably leads a cell to self-destruct. Controlling
this process are a large family of B cell lymphoma
(Bcl-2) protein homologs, which comprise anti- and
pro-apoptotic proteins (Cory and Adams 2002).
Additionally, a further group of heterogeneous pro-
teins, the BH3 family, which act as pro-apoptotic
proteins by interacting with and inhibiting the anti-
apoptotic Bcl-2 proteins (Youle and Strasser 2008).
Focusing on the mitochondrial apoptotic pathway,
induction is shown to occur in response to stress
including DNA damage, oxidative damage, starvation,
serum starvation, chemotherapeutic agents and excess
Ca2? (Sattler and Tymianski 2000; Wang and Youle
2009). Such apoptotic stimuli causes Bax and Bak,
which under normal conditions shuttle between the
cytosol and the outer mitochondrial membrane
(OMM), to change conformation and oligomerise in
the OMM (Griffiths et al. 1999; Hsu et al. 1997;
Wolter et al. 1997). This enables permeabilization of
the mitochondrial membrane for release of apoptotic
proteins, including cytochrome c, which in turn is
essential for activating the caspase cascade for
programmed cell death to occur (Liu et al. 1996;
Lovell et al. 2008; Wang and Youle 2009).
One carbon metabolism
One-carbon metabolism comprises a network of
biosynthetic reactions that occur in the cytoplasm
and mitochondria to provide one-carbon units as the
building blocks for cellular biosynthesis, methylation
and redox reactions (reviewed by Rosenzweig et al.
2018). The one-carbon units are derived from different
nutrients, largely the non-essential amino acids serine
and glycine (Kalhan and Hanson 2012), which can
then flow into the folate cycle and the methionine
cycle. Serine and glycine can be sourced exogenously
or generated de novo from glucose along a series of
enzymatic reactions collectively referred to as the
serine synthesis pathway (SSP) (Locasale et al. 2011).
The folate cycle can occur in the cytoplasm but occurs
more favourably in the mitochondrion (Ducker et al.
2016) with each compartment having their own
enzymatic machinery.
The folate cycle first reduces folic acid to tetrahy-
drofolate (THF), the biologically active form (New-
man and Maddocks 2017). THF can then be
methylated by serine hydroxymethyltransferase
(SHMT) or glycine decarboxylase (GDLC), into
methyl-THF in the presence of serine or glycine
respectively. Methyl-THF then undergoes a series of
redox reactions catalysed by the mitochondrial or
cytoplasmic isoforms of methylenetetrahydrofolate
dehydrogenase (MTHFD1/2/1L). Notably, a consid-
erable amount of reduced nicotinamide adenine din-
ucleotide phosphate (NADPH) production, equal to
that of the pentose phosphate pathway occurs by the
mitochondrial folate pathway (Fan et al. 2014). The
generation of formate through this pathway can then
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feed into purine synthesis or alternatively methyl-THF
may enter into the methionine cycle, important for
epigenetic modifications, and methylation reactions
(Finkelstein 1990) (Fig. 1).
In the methionine cycle methylation of homocys-
teine by methyl-THF, forms the only essential sul-
phur-containing amino acid, methionine (Finkelstein
2000). Moreover generation of ATP during the folate
cycle can then be used in the methionine cycle to
synthesise S-adenosyl-methionine (SAM) by reacting
with methionine (Markham et al. 1980); SAM is the
major universal methyl-donor in living organisms
(Chiang et al. 1996). Amongst a broad range of
methylation reactions required for cellular function-
ing, there is a high demand for mitochondrial
10-formyl-THF which is required for the formylation
of the initiator methionine tRNA for protein transla-
tion in the mitochondria (Tucker et al. 2011). To
complete the cycle homocysteine can also be regen-
erated by the demethylation of SAM. Of note homo-
cysteine can also branch off into the transsulfuration
pathway for the generation of the antioxidant glu-
tathione (Zhou et al. 2017). Thus, mitochondria
support one-carbon redistribution essential for purine,
ATP, NADP and glutathione synthesis and methyla-
tion reactions, which are crucial for controlling cell
fate and homeostasis.
Mitochondrial genetics
The majority of mammalian somatic cells contain
many mitochondria. mtDNA copy number is thought
to reach 103–104 per cell (Lightowlers et al. 1997),
with mature oocytes containing at least 105 copies
(Shoubridge and Wai 2007). mtDNA contains 37
genes, which encode 13 protein subunits of the
mitochondrial ETC, the mitochondrial translation
machinery, in the form of a 12S and 16S ribosomal
RNA (rRNA), and a full complement of 22 transfer
RNAs (tRNAs). The mitochondrial genome has a
unique genetic code (Barrell et al. 1979) with an
extremely economical organisation, lacking introns,
and only having a few noncoding bases between some
genes (Anderson et al. 1981). The only exception to
this being the displacement loop (D-loop) region,
which contains the three promoter regions of the H-
and L-strand (Kasamatsu et al. 1971). Moreover, there
is overlap of some protein encoding genes e.g. ND4
and ND4L, and the transcription termination codon for
many mRNAs is not encoded but is instead generated
by post-transcriptional polyadenylation (Anderson
et al. 1981; Ojala et al. 1981).
mtDNA lacks histones and is packaged into nucle-
oprotein complexes called nucleoids, containing sin-
gle or multiple mtDNAmolecules (Bogenhagen 2012;
Satoh and Kuroiwa 1991). The most abundant protein
responsible for co-operatively binding and wrapping
mtDNA to form these compact segregated units is the
HMG-box protein, mitochondrial transcription factor
A (TFAM) (Kaufman et al. 2007; Parisi and Clayton
1991). However, other nucleoid core proteins which,
like TFAM, also play roles in mtDNA replication and
transcription include the mitochondrial DNA poly-
merase c (POLc), mitochondrial RNA polymerase
(POLRMT), mitochondrial single-strand binding pro-
tein (mtSSB) and the mitochondrial TWINKLE heli-
case (Bogenhagen et al. 2008). Towards the periphery
of nucleoids other proteins involved in translation and
complex assembly and those in the IMM e.g. pro-
hibitin, are present, associating the mtDNA with the
IMM (Bogenhagen et al. 2008; Falkenberg et al.
2007).
The multi-copy nature of mtDNA means that cells
rarely exist in a state where all copies are identical
(homoplasmy), in fact, the vast majority of cells
contain a mixture of wild-type (WT) and mutated
molecules, termed heteroplasmy (Stewart and Chin-
nery 2015; Taylor and Turnbull 2005). However, the
high copy number and highly recessive nature of
mtDNA mutations within a cell allows WT mtDNA to
compensate for mutated mtDNA up to a certain point
(Sciacco et al. 1994). Beyond a critical threshold
however, a biochemical defect occurs. The threshold
level is dependent on the tissue type, and it’s metabolic
demand (Rossignol et al. 1999), as well as the number
of residual WT mtDNA copies (Sciacco et al. 1994).
mtDNA mutations and mitochondrial dysfunction
in ageing tissues
The mt.8344A[G transition in the tRNALys gene,
and mt.3243A[G transition in the tRNALeu gene,
were the first mtDNA point mutations detected to be
present at higher levels in homogenate ageing tissues
such as brain, heart, liver, kidney and skeletal muscle
(Mu¨nscher et al. 1993; Zhang et al. 1993). Nekhaeva
123
Biogerontology
et al. then used single-cell sequence analysis and
showed that a subset of normal ageing buccal epithe-
lial cells and cardiomyocytes contain mtDNA muta-
tions at high levels of heteroplasmy or homoplasmy
(Nekhaeva et al. 2002). Since this discovery, an age-
related increase in the frequency of cells with high
level mtDNA point mutations resulting in OXPHOS
defects have been detected in a number of ageing
mitotic tissues such as colon, stomach, small intestine,
oesophagus and liver (Fellous et al. 2009b; Greaves
et al. 2010; McDonald et al. 2008; Taylor et al. 2003).
mtDNA point mutations in ageing tissues appear to
occur at random throughout the mitochondrial gen-
ome; however, the mechanism underlying their gen-
eration has been an area of much debate. The
mitochondrial theory of ageing postulates that due to
its close proximity to the mitochondrial respiratory
chain, the mtDNA is highly susceptible to oxidative
damage (Miquel et al. 1980). This can result in base
modifications, sugar damage, strand breaks and abasic
sites (Wang et al. 1998). Commonly produced base
lesions are 7,8-dihydro-8-oxo-20-deoxyguanoisine (8-
oxo-dG) (Bohr 2002) and thymine glycols (Wang et al.
1998). The formation of 8-oxod-G is suggested to
induce G:T transversions by POLc, whereas thymine
glycols are thought to be less mutagenic and instead
block polymerisation (Alexeyev et al. 2013; Hanes
et al. 2006). Analysis of mutational spectra from aged
mitotic and post-mitotic human tissues has shown that
the pattern is not consistent with the G:C to T:A
transversions caused by oxidative damage (Greaves
et al. 2014; Kennedy et al. 2013), but instead, the most
common mutation type were G:C to A:T transitions.
These are more likely caused by errors during mtDNA
replication and/or spontaneous cytosine deamination
(Zheng et al. 2006). Along with multiple studies of
mtDNA mutational spectra in transgenic mouse mod-
els (reviewed by Kauppila et al. 2017), these data
suggest a limited role for ROS in age-related mtDNA
point mutation generation.
Within ageing mitotic cells, mtDNA point muta-
tions are commonly present at high levels of hetero-
plasmy or homoplasmy. How one mutated mtDNA
molecule clonally expands to become the dominant
species within a cell, resulting in a biochemical defect,
has been debated for a number of years without a
definitive mechanism being agreed upon. In 1997 de
Grey suggested that individual cells with mutated
mtDNA and subsequent respiratory chain deficiency
would result in the production of fewer ROS, resulting
in lower levels of mitochondrial membrane damage.
Mitochondria with WT mtDNA and with normal
respiratory chain function would produce more ROS
and suffer a higher rate of oxidative membrane
damage, and thus more likely be targeted for lysoso-
mal degradation. Mitochondria with mutated mtDNA
would therefore have a selective survival advantage
and rapidly populate the cell (de Grey 1997). How-
ever, this ‘survival of the slowest’ hypothesis (Kowald
and Kirkwood 2000), only explains clonal expansion
after a respiratory deficiency has been reached and
does not acknowledge the dynamic reticular network
of mitochondria. Computational simulations have
suggested that simple genetic drift is able to explain
the clonal expansion of mtDNA mutations in mitotic
cell populations (Coller et al. 2001; Stamp et al. 2018).
These models suggest that the initial mutational events
occur early in life, then through successive cycles of
mtDNA replication followed by random segregation at
cell division, mutations are either lost or can expand to
become the dominant species within the cell, resulting
in mitochondrial dysfunction. Additionally, as the
stem cells of mitotic tissues are the most-long lived
cell types, once a mtDNA mutation becomes fixed
within a stem cell, this will be transmitted to all of the
stem cell progeny. This results in the patches of cells
with OXPHOS defects that have been documented in
ageing stem-cell derived populations (Fellous et al.
2009a; McDonald et al. 2008; Stamp et al. 2018).
In addition to the most commonly documented
consequences of mtDNA mutations, which are defects
in OXPHOS, a number of groups have investigated the
downstream consequences of OXPHOS dysfunction
on other aspects of mitochondrial metabolism. Nikka-
nen et al. analysed skeletal muscle from a mouse
model of progressive mtDNAmutagenesis caused by a
mutation in the TWINKLE gene. They detected an
upregulation of the mitochondrial folate cycle and
purine synthesis and increased glucose uptake for de
novo serine and glutathione synthesis in response to
mitochondrial stress (Nikkanen et al. 2016), which
was subsequently shown to be controlled via the
mechanistic (mammalian) target of rapamycin
(mTOR) complex I (mTORC1) pathway (Khan et al.
2017). These pathways were also confirmed to be
upregulated in blood and muscle of patients with
mitochondrial diseases (Buzkova et al. 2018). Folate-
driven one carbon metabolism is the major anabolic
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biosynthesis pathway, which provides one-carbon
units for cell growth and repair. Bao et al. showed
that a number of genes in the de novo SSP were
regulated at the transcriptional level by the transcrip-
tion factor ATF4, and ATF4 mediated rewiring of
mitochondrial one-carbon metabolism following
ethidium bromide mediated depletion of mtDNA in
cell lines (Bao et al. 2016). These data show that cells
with mitochondrial dysfunction are able to rewire their
metabolism in an attempt to maintain cellular
homeostasis.
Despite the plethora of evidence showing an
association of mtDNA mutations with human ageing,
it is still not clear whether these are a cause or
consequence of ageing. The mitochondrial mutator
mouse model was developed to address this directly.
The mutator mouse harbours an error prone mito-
chondrial polymerase gamma, which causes the
accumulation of mtDNA mutations systemically with
age (Kujoth et al. 2005; Trifunovic et al. 2004). This
results in a premature ageing phenotype with greying
of hair, kyphosis, reduced subcutaneous fat, osteo-
porosis, reduced fertility, anaemia and heart enlarge-
ment leading to a reduced lifespan (\ 12 months). A
number of other groups have used the mutator mouse
model to investigate how mitochondrial dysfunction
may specifically contribute to ageing processes in
specific cell and tissues types. These studies have
shown defects in innate immunity regulation (Niu
et al. 2007), inflammation (Logan et al. 2014), stem
cell activity (Ahlqvist Kati et al. 2012; Chen et al.
2009) and levels of apoptosis (Norddahl Gudmundur
et al. 2011). Taken together these studies suggest that,
in this model, mitochondrial dysfunction can drive
ageing through a combination of perturbations in ROS
signalling pathways and defects in cellular bioener-
getics (Baines et al. 2014).
Mitochondrial dysfunction in cancer
Altered mitochondrial metabolism in cancer cells
Mitochondrial function was first proposed to play a
role in cancer biology in the early twentieth century.
Cancer cells exhibiting rapid growth and proliferation
rates in harsh tumour microenvironments, must adapt
their metabolism to meet the high energy demands
required for these processes. Warburg first
documented tumours undergoing a metabolic switch
with increased levels of glucose uptake and a high rate
of glycolysis, even in the presence of oxygen (War-
burg 1913, 1956a, b; Warburg et al. 1927). This
property of tumour cells, termed the ‘Warburg effect’,
is still utilised in clinical monitoring of oncology
patients by positron-emission tomography (PET),
which allows detection of high glucose uptake by
primary and metastatic tumours (Di Chiro et al. 1982;
Hawkins and Phelps 1988). There is a positive
correlation between tumour aggressiveness and glu-
cose uptake (Kunkel et al. 2003). Energy derivation
via glycolysis may be seen as a disadvantage, yielding
only two ATP molecules per glucose molecule instead
of 36 ATP molecules through complete aerobic
oxidation. However, switching from mitochondrial
OXPHOS to aerobic glycolysis may permit adaptation
to the hypoxic tumour microenvironment. ATP gen-
eration by glycolysis can occur at a faster rate than
OXPHOS (Pfeiffer et al. 2001) and diversion of
pyruvate away from OXPHOS to lactate production
and anabolic processes such as the pentose phosphate
pathway for nucleotide, lipid and amino acid gener-
ation, may aid rapid proliferation (Giampazolias and
Tait 2016).
Currently there is still much support for the
Warburg Effect in tumours. Warburg, however, pro-
posed aerobic glycolysis was in fact due to a defect in
mitochondria (Warburg 1956b), suggesting mitochon-
dria were dispensable for the oncogenic process.
However, the recognition of mitochondrial outer
membrane permeabilisation as a critical point in
programmed cell death (Zamzami et al. 1995) and
earlier reports of the mitochondrial membrane poten-
tial being higher in cancer cells (Chen 1988), impli-
cated the dysfunctional control of mitochondria to be
crucial for the evasion of apoptosis by cancer cells
(Hanahan and Weinberg 2000). A significant involve-
ment and dependence of mitochondrial functioning in
malignant transformation and tumour progression as
well as the influence in response to anticancer
treatments has become apparent (Porporato et al.
2017). Subsequently, a vast range of studies have
appealed for aberrant functioning of mitochondria to
be investigated as potential targets for the develop-
ment of cancer therapies (Fulda et al. 2010; Pustyl-
nikov et al. 2018). Drugs that target mitochondria to
re-sensitise cells to apoptosis for example, have been
clinically approved for use in treatment e.g.
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venetoclax for chronic lymphocytic leukemia (Ashke-
nazi et al. 2017; Sarosiek and Letai 2016).
Metabolic rewiring in tumours is not limited to
increases in glucose uptake for ATP synthesis by
glycolysis, or upregulation of the pentose phosphate
pathway. The harsh and constantly evolving tumour
microenvironment requires other metabolic circuits
and entries between mitochondrial and cytoplasmic
compartments to be suitably co-ordinated and selected
for tumour survival. For example, increased glutamine
consumption and metabolism feeds into the TCA
cycle for ATP synthesis, fatty acid and nucleotide
synthesis, is seen in tumours and has been explored as
therapeutic channel (Altman et al. 2016). Addition-
ally, cancer cells are shown to recruit and utilise other
carbon sources such as acetate, glycine and serine to
adapt to and support their growth and proliferation in
the tumour microenvironment (Maddocks et al. 2013;
Mashimo et al. 2014). The heterogeneity of conditions
such as oxygenation, within a tumour has also been
shown to set up a variation in metabolic profiles and
symbiosis between tumour regions for the exchange of
metabolites. Tumour regions under hypoxia utilising
glucose for glycolysis and releasing lactic acid, are
shown to fuel oxidative tumour cells, thus sparing
glucose for neighbouring hypoxic tumour regions
(Feron 2009; Sonveaux et al. 2008).
Nuclear DNA mutations in metabolism genes
in cancer
The rewiring and plasticity of mitochondrial metabo-
lism and signalling in aiding tumourigenesis has been
highlighted from the gene level up to the protein and
functional level. At the genetic level tumours have
been reported to harbour mutations in nuclear encoded
enzymes involved in metabolism and accumulate
associated oncometabolites, thought to increase
tumorigenesis. In numerous types of tumours, muta-
tions and changes in activity of TCA cycle enzymes
have been detected including citrate synthase, aconi-
tase (Schlichtholz et al. 2005; Singh et al. 2006),
fumarate hydratase (Tomlinson et al. 2002), succinate
dehydrogenase (Bardella et al. 2011) and isocitrate
dehydrogenase (Balss et al. 2008). However, depend-
ing on the anatomical location of the tumour, some of
these genes can be found to be either upregulated or
downregulated, and induce different oncogenic pro-
cesses. Mutations of isocitrate dehydrogenase for
example are frequently found in brain tumours (Balss
et al. 2008), and are suggested to raise 2-hydroxyg-
lutarate levels (Dang et al. 2009), to help drive
oncogenic promoting processes through DNA hyper-
methylation (Figueroa et al. 2010) and histone mod-
ification (Lu et al. 2012). Moreover, in cervical
carcinoma cell lines mutations in citrate synthase are
reported to cause downregulation in support of a
glycolytic switch (Lin et al. 2012). On the other hand
upregulation of citrate in pancreatic cancer has been
hypothesised to favour synthesis of fatty acids (Sch-
lichtholz et al. 2005), which fuels pancreatic tumour
progression (Blum and Kloog 2014; Witkiewicz et al.
2008). The heterogeneity between tumour types and
requirements is therefore extremely variable, and a
generic role for these enzymes in cancer is somewhat
debatable.
mtDNA mutations in cancer cells
The detection of somatic mutations in the mtDNA of
tumours has been documented in a range of cancers,
such as colon, breast, liver and lung cancers (Chatter-
jee et al. 2006). Moreover the importance of mtDNA
mutations in the metabolic rewiring and functioning of
cancer cells is amplified by a loss of tumourigenicity
by brain and breast cancer cells after the depletion of
mtDNA (Cavalli et al. 1997; Weinberg et al. 2010).
Comprising most protein subunits and the largest of all
respiratory chain complexes, mtDNA mutations in
complex I are the most commonly reported in tumours
(reviewed by Gaude and Frezza 2014). Mutations in
complex I mtDNA genes have been suggested to be
required for a glycolytic switch (Calabrese et al. 2013)
and ROS-driven metastasis (He et al. 2013; Ishikawa
et al. 2008) by cancer cells. However, there appears to
be a diverse tumorigenic potential of different mtDNA
mutations affecting complex I activity with severe
deficiency reducing tumorigenesis in osteosarcoma
cells in vitro and in vivo (Iommarini et al. 2014).
Mutations in mtDNA encoding genes of complexes III
(Dasgupta et al. 2009), IV and V are also thought to
influence tumourigenesis. Mutations in Complex III
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are reported to increase cancer cell growth through an
increase in ROS production and apoptotic resistance
(Dasgupta et al. 2009).
There are contrasting reports on the role of mtDNA
and nuclear DNA encoded complex IV subunits in
cancer progression. An upregulation of nuclear
encoded subunits of complex IV have been detected
in leukaemia cells which increases cellular OXPHOS
and exacerbates ROS production (Chen and Pervaiz
2009), whereas mutations of mtDNA encoded com-
plex IV subunits which decrease OXPHOS and
increase ROS production have been detected in
prostate cancer and ovarian tumours (Petros et al.
2005). This suggests a bias towards oncogenic
promotion by nuclear encoded complex IV subunits,
with mtDNA encoded complex IV subunit activity
supressing tumour growth (Gaude and Frezza 2014).
Complex V is the final enzyme of the OXPHOS
system and forms part of the permeability transition
pore for calcium flux and apoptosis. Mutations in
complex V have been suggested to cause apoptotic
resistance, promoting cancer cell survival (Shidara
et al. 2005). An elegant study by Gaude et al.
engineered a cytoplasmic hybrid (cybrid) cell line
with various heteroplasmy levels of the m.8993 T[G
mutation in MT-ATP6, termed mTUNE lines. They
showed that at high levels of heteroplasmy mTUNE
cells made a glycolytic switch that was coupled by
malate dehydrogenase 1 to reductive carboxylation of
glutamine—a process that drives cell proliferation and
migration. This switch was lost when the hetero-
plasmy level of the m.8993T[G mutations was low
(Gaude et al. 2018). These data provide evidence that
high-level heteroplasmic mtDNA mutations can pro-
mote an oncogenic metabolic phenotype. Other evi-
dence suggesting that mtDNA mutations can promote
a pro-oncogenic metabolic phenotype is the observed
upregulation of de novo serine synthesis and one
carbon metabolism that has been shown to occur in
both cell lines with mtDNA mutations or depletion
(Bao et al. 2016), and in animal models of mitochon-
drial myopathy (Khan et al. 2017; Nikkanen et al.
2016). Upregulation of these pathways has also been
shown to promote cancer cell growth in animal models
of intestinal cancer and lymphoma (Maddocks et al.
2017).
Alongside tumour growth and proliferation, the
multi-step process of metastatic disease development
also requires certain aspects of mitochondrial func-
tioning. Metastasis first involves the epithelial to
mesenchymal transition of cancer cells to allow
migration (Nieto et al. 2016). The invasive potential
of cancer cells during this transition is suggested to be
supported and manipulated by mitochondrial biogen-
esis, OXPHOS and dynamics (Caino et al. 2016;
LeBleu et al. 2014), as well as mitochondrial metabo-
lites such as fumarate (Sciacovelli et al. 2016).
Moreover, assays in mice showed high metastatic
potential of cells with mutations in MT-ND6 of
complex I, linking metastasis with the overproduction
of ROS (Ishikawa et al. 2008). Other studies have
further identified metastatic dissemination to be pro-
moted by mitochondrial ROS overproduction and
associated signal transduction cascades (Comito et al.
2011; Porporato et al. 2014). Protection of cancer cells
against ROS is partially due to increased glucose flux
through the pentose phosphate pathway leading to
antioxidant production, thus promoting their survival
(Schafer et al. 2009). However, beyond a certain
threshold, levels of ROS may inhibit metastasis
(Piskounova et al. 2015). A recent study has shown
that during metastasis, detachment of the tumour cells
from the extracellular matrix followed by dissemina-
tion through the circulation is a rate limiting step in the
process. This process is enhanced by reduced mito-
chondrial capacity and a reliance on glycolysis for
ATP production which is supported by reductive
carboxylation of glutamine; if this is prevented there is
induction of ROS production and cell death, and
inhibition of metastatic spread (Labuschagne et al.
2019).
Conclusions
Metabolic rewiring is an important feature of many
cancer types with metabolism moved away from
OXPHOS towards anabolic pathways, providing
biosynthetic building blocks for cell proliferation
andmigration.Mutations of the mtDNA are frequently
observed in a number of solid tumour types (Ju et al.
2014; Salas et al. 2005) and are very common in
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normal ageing mitotic tissues. Importantly, non-
cancer cells with OXPHOS defects due to mtDNA
mutations upregulate some of the same metabolic
pathways as those upregulated in cancers; posing an
interesting question as to whether ageing cells with
mtDNA mutations provide a favourable metabolic
environment for tumour growth following transfor-
mation. Alternatively, as mtDNA mutations clonally
expand rapidly in proliferating cells, this may occur
during the tumour development, generating subsets of
cell clones with a more favourable metabolic profile
that out-compete other clones and promote tumour
progression and metastasis (Fig. 2). Whether mtDNA
mutations are drivers or passengers in the oncogenic
process is still a matter of debate. It is likely that they
will have differential effects depending on the tissue of
origin and the specific mtDNA mutation present. In
addition, further research sub-classifying tumours into
those with and without mtDNA mutations and the
effect of those mutations on tumour cell metabolism,
may help to elucidate the functional effects of such
mutations in the tumorigenic process, and whether
mtDNAmutations cause metabolic vulnerabilities that
may be exploited therapeutically.
Fig. 2 Schematic to show the hypothesised mechanisms by
which mitochondrial DNA mutations may become manifest in
tumours and either inhibit or promote tumour growth and/or
progression. WT mtDNA is depicted in blue. Mutated mtDNA
molecules conferring an advantageous metabolic phenotype for
tumour growth are shown in green, and those causing a
detrimental metabolic phenotype are shown in red
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